Q3 EPS Estimate for TriSalus Life Sciences Cut by Analyst

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Equities research analysts at Northland Capmk reduced their Q3 2025 earnings estimates for TriSalus Life Sciences in a research note issued on Wednesday, August 13th. Northland Capmk analyst C. Byrnes now expects that the company will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.18). The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Northland Capmk also issued estimates for TriSalus Life Sciences’ Q4 2025 earnings at ($0.16) EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The company had revenue of $11.21 million for the quarter, compared to analyst estimates of $10.69 million.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $4.55 on Friday. TriSalus Life Sciences has a one year low of $3.42 and a one year high of $6.03. The company has a 50 day moving average price of $4.78 and a 200 day moving average price of $5.20. The firm has a market capitalization of $172.17 million, a price-to-earnings ratio of -3.86 and a beta of 0.48.

Insider Buying and Selling

In related news, insider Richard Marshak sold 6,597 shares of the company’s stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the completion of the transaction, the insider owned 69,101 shares of the company’s stock, valued at approximately $357,943.18. This represents a 8.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 16,125 shares of company stock worth $83,528 over the last ninety days. Corporate insiders own 27.50% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

Several large investors have recently made changes to their positions in TLSI. Bank of America Corp DE increased its position in shares of TriSalus Life Sciences by 1.8% in the second quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock worth $1,030,000 after acquiring an additional 3,374 shares in the last quarter. Geode Capital Management LLC increased its position in shares of TriSalus Life Sciences by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 204,137 shares of the company’s stock worth $1,023,000 after acquiring an additional 3,710 shares in the last quarter. Connective Capital Management LLC boosted its stake in shares of TriSalus Life Sciences by 12.8% in the second quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after purchasing an additional 3,717 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of TriSalus Life Sciences in the second quarter valued at $29,000. Finally, Northern Trust Corp boosted its stake in shares of TriSalus Life Sciences by 22.7% in the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after purchasing an additional 5,936 shares during the period. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.